Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

As the Biden administration is proposing drugs like Ozempic and Wegovy be covered by Medicare and Medicaid, Black people need ...

Recently, weight loss drugs like Ozempic and Wegovy have gained widespread attention, transforming the landscape of obesity management and weight loss treatments. Initially developed for the treatment ...

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more effective? In a press release, Lilly announced that in its latest trial ...

People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.

On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy, Lilly said. "I am not the only ...

Ozempic and Wegovy might be making it harder for physicians to guide patients toward lifestyle changes − the real key to long ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...

After 72 weeks, those who received weekly injections of Zepbound lost 20.2 percent of their body weight, or just over 50 pounds, while Wegovy users lost 13.7 percent, or more than 33 pounds.